Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3686) 3686
Publication (602) 602
Newsletter (170) 170
Newspaper Article (27) 27
Book Chapter (24) 24
Book Review (16) 16
Conference Proceeding (12) 12
Magazine Article (10) 10
Dissertation (4) 4
Trade Publication Article (3) 3
Paper (2) 2
Transcript (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dasatinib (3425) 3425
humans (2452) 2452
index medicus (2188) 2188
oncology (1403) 1403
imatinib (1103) 1103
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1006) 1006
hematology (988) 988
chronic myeloid leukemia (894) 894
female (891) 891
male (867) 867
imatinib mesylate (851) 851
nilotinib (828) 828
pyrimidines - therapeutic use (827) 827
protein kinase inhibitors - therapeutic use (816) 816
chronic myelogenous leukemia (784) 784
chronic myeloid-leukemia (710) 710
middle aged (692) 692
antineoplastic agents - therapeutic use (671) 671
cancer (668) 668
thiazoles - therapeutic use (630) 630
protein kinase inhibitors - pharmacology (604) 604
adult (597) 597
pyrimidines - pharmacology (597) 597
animals (583) 583
aged (562) 562
leukemia (544) 544
benzamides (536) 536
research (517) 517
hemic and lymphatic diseases (467) 467
thiazoles - pharmacology (467) 467
cell line, tumor (458) 458
tyrosine (455) 455
treatment outcome (443) 443
bcr-abl (434) 434
care and treatment (427) 427
piperazines - therapeutic use (425) 425
therapy (414) 414
tyrosine kinase inhibitors (413) 413
protein-tyrosine kinases - antagonists & inhibitors (406) 406
mutation (391) 391
tyrosine kinase inhibitor (390) 390
mice (385) 385
antineoplastic agents - pharmacology (369) 369
pyrimidines - adverse effects (353) 353
drug therapy (338) 338
pyrimidines - administration & dosage (323) 323
drug resistance, neoplasm (319) 319
leukemia, myelogenous, chronic, bcr-abl positive - genetics (316) 316
resistance (314) 314
fusion proteins, bcr-abl - genetics (313) 313
article (312) 312
pharmacology & pharmacy (311) 311
protein kinase inhibitors - adverse effects (305) 305
cml (299) 299
analysis (294) 294
kinases (281) 281
follow-up (275) 275
tyrosine kinase (269) 269
protein kinase inhibitors - administration & dosage (262) 262
chronic-phase (259) 259
aged, 80 and over (256) 256
thiazoles - adverse effects (249) 249
activation (245) 245
thiazoles - administration & dosage (245) 245
chemotherapy (244) 244
antineoplastic agents - adverse effects (241) 241
dosage and administration (237) 237
health aspects (237) 237
phosphorylation (236) 236
leukemia, myelogenous, chronic, bcr-abl positive - pathology (235) 235
medicine & public health (230) 230
apoptosis (226) 226
hematology, oncology and palliative medicine (225) 225
src-family kinases - antagonists & inhibitors (225) 225
young adult (223) 223
antineoplastic agents (222) 222
fusion proteins, bcr-abl - antagonists & inhibitors (220) 220
dasatinib - therapeutic use (215) 215
cell proliferation - drug effects (213) 213
src (212) 212
src-family kinases - metabolism (210) 210
expression (209) 209
genetic aspects (208) 208
apoptosis - drug effects (207) 207
in-vitro (206) 206
cytogenetic responses (203) 203
piperazines - pharmacology (200) 200
philadelphia chromosome (197) 197
cell biology (194) 194
antimitotic agents (193) 193
abridged index medicus (192) 192
antineoplastic agents - administration & dosage (192) 192
kinase inhibitor (190) 190
cells (189) 189
dasatinib - pharmacology (189) 189
imatinib-resistant (188) 188
signal transduction - drug effects (185) 185
antineoplastic combined chemotherapy protocols - therapeutic use (184) 184
protein-tyrosine kinase (184) 184
adolescent (175) 175
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3690) 3690
Japanese (51) 51
Chinese (29) 29
French (27) 27
Polish (24) 24
Russian (22) 22
Spanish (17) 17
German (14) 14
Czech (9) 9
Korean (9) 9
Portuguese (6) 6
Turkish (6) 6
Danish (2) 2
Hebrew (2) 2
Italian (2) 2
Slovenian (2) 2
Finnish (1) 1
Hungarian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Systematic Review of Non-Conventional Dosing of Oral Anticancer Therapies in Malignant Haematology
by Djebbari, Faouzi and Stoner, Nicola and Lavender, Verna
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5915 - 5915
Abstract Introduction Survival outcomes for patients with lymphoid, myeloid and plasma cell malignancies, have improved with the use of oral small molecule... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Simultaneous determination of 6-mercaptopruine, 6-thioguanine and dasatinib as three important anticancer drugs using nanostructure voltammetric sensor employing Pt/MWCNTs and 1-butyl-3-methylimidazolium hexafluoro phosphate
by Karimi-Maleh, Hassan and Shojaei, Abdollah Fallah and Tabatabaeian, Khalil and Karimi, Fatemeh and Shakeri, Shahryar and Moradi, Reza
Biosensors and Bioelectronics, ISSN 0956-5663, 12/2016, Volume 86, pp. 879 - 884
6-Mercaptopurine, 6-thioguanine and dasatinib are three important anticancer drugs with high adverse effects in human body. In this study, a... 
6-Thioguanine | Dasatinib | Pt/MWCNTs | 6-Mercaptopurine | Sensor | Ionic liquid | ELECTROCHEMISTRY | CHEMISTRY, ANALYTICAL | MEDIATOR | NANOSCIENCE & NANOTECHNOLOGY | FOLIC-ACID | NICOTINAMIDE ADENINE-DINUCLEOTIDE | CARBON-PASTE ELECTRODE | BIOPHYSICS | HUMAN PERIPHERAL-BLOOD | GLUTATHIONE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | NANOTUBES | NANOCOMPOSITE | SAMPLES | HPLC | Humans | Imidazoles - chemistry | Thioguanine - urine | Equipment Design | Mercaptopurine - chemistry | Mercaptopurine - urine | Platinum - chemistry | Conductometry - instrumentation | Sensitivity and Specificity | Dasatinib - urine | Dasatinib - analysis | Metal Nanoparticles - ultrastructure | Reproducibility of Results | Thioguanine - chemistry | Metal Nanoparticles - chemistry | Nanotubes, Carbon - ultrastructure | Antineoplastic Agents - analysis | Complex Mixtures - chemistry | Dasatinib - chemistry | Antineoplastic Agents - chemistry | Antineoplastic Agents - urine | Nanotubes, Carbon - chemistry | Complex Mixtures - analysis | Mercaptopurine - analysis | Thioguanine - analysis | Equipment Failure Analysis | Phosphates | Sensors | Thioguanine | Polyols | Analysis | Mercaptopurine | Fluorides | Electrodes | Drugs | Human body | Nanostructure | Biosensors | Carbon
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Naïve chronic myeloid leukemia patients trial
by Cortes, Jorge E and Saglio, Giuseppe and Kantarjian, Hagop M and Baccarani, Michele and Mayer, Jiří and Boqué, Concepción and Shah, Neil P and Chuah, Charles and Casanova, Luis and Bradley-Garelik, Brigid and Manos, George and Hochhaus, Andreas
Journal of Clinical Oncology, ISSN 0732-183X, 07/2016, Volume 34, Issue 20, pp. 2333 - 2340
Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients (DASISION) trial,... 
TYROSINE KINASE INHIBITORS | CHRONIC MYELOGENOUS LEUKEMIA | EARLY MOLECULAR RESPONSE | INTERFERON-ALPHA | BCR-ABL1 TRANSCRIPT LEVELS | THERAPY | CHRONIC-PHASE | ONCOLOGY | SUBOPTIMAL RESPONSE | FOLLOW-UP | EUROPEAN-LEUKEMIANET | Humans | Leukemia, Myeloid, Chronic-Phase - drug therapy | Middle Aged | Dasatinib - therapeutic use | Leukemia, Myeloid, Chronic-Phase - mortality | Fusion Proteins, bcr-abl - genetics | Imatinib Mesylate - therapeutic use | Imatinib Mesylate - adverse effects | Adult | Aged | Dasatinib - adverse effects | Mutation | Leukemia, Myeloid, Chronic-Phase - genetics | Hema7 | Bios3 | To19 | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia
by Miura, Masatomo
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2015, Volume 38, Issue 5, pp. 645 - 654
Imatinib, nilotinib, and dasatinib are tyrosine kinase inhibitors (TKIs) that have become first-line treatments for Philadelphia chromosome-positive chronic... 
imatinib | dasatinib | nilotinib | therapeutic drug monitoring | Nilotinib | Therapeutic drug monitoring | Dasatinib | Imatinib | CHRONIC MYELOGENOUS LEUKEMIA | EXPOSURE-RESPONSE ANALYSIS | PHASE-3 TRIAL DASISION | STANDARD-DOSE IMATINIB | FOLLOW-UP | KINASE INHIBITORS | TROUGH CONCENTRATION | PLASMA-LEVELS | ACUTE LYMPHOBLASTIC-LEUKEMIA | PHARMACOLOGY & PHARMACY | CLINICAL-RESPONSE | Pyrimidines - administration & dosage | Pyrimidines - blood | Humans | Dasatinib - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein Kinase Inhibitors - blood | Dasatinib - blood | Protein Kinase Inhibitors - administration & dosage | Imatinib Mesylate - therapeutic use | Dasatinib - administration & dosage | Imatinib Mesylate - blood | Antineoplastic Agents - adverse effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Imatinib Mesylate - adverse effects | Imatinib Mesylate - administration & dosage | Pyrimidines - adverse effects | Antineoplastic Agents - blood | Dasatinib - adverse effects | Drug Monitoring
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes
by Zhao, Qian and Ouyang, Xiaohu and Wan, Xiaobo and Gajiwala, Ketan S and Kath, John C and Jones, Lyn H and Burlingame, Alma L and Taunton, Jack and Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Journal of the American Chemical Society, ISSN 0002-7863, 01/2017, Volume 139, Issue 2, pp. 680 - 685
Protein kinases comprise a large family of structurally related enzymes. A major goal in kinase-inhibitor development is to selectively engage the desired... 
ACTIVATION | AFFINITY-BASED PROBES | KINOME | CHEMICAL PROTEOMICS | INHIBITOR SELECTIVITY | BMS-354825 | DASATINIB | CHEMISTRY, MULTIDISCIPLINARY | Cells, Cultured | Protein Kinases - chemistry | Sulfinic Acids - chemistry | Dasatinib - chemistry | Drug Delivery Systems | Dasatinib - pharmacology | Molecular Probes - chemistry | Models, Biological | Mass Spectrometry | Molecular Structure | Adenosine Triphosphate - chemistry | Lysine - chemistry | Binding Sites | Usage | Fluorides | Chemical properties | Research | Mass spectrometry | Adenosine triphosphate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text An Immunosuppressive Antibody–Drug Conjugate
by Wang, Rongsheng E and Liu, Tao and Wang, Ying and Cao, Yu and Du, Jintang and Luo, Xiaozhou and Deshmukh, Vishal and Kim, Chan Hyuk and Lawson, Brian R and Tremblay, Matthew S and Young, Travis S and Kazane, Stephanie A and Wang, Feng and Schultz, Peter G
Journal of the American Chemical Society, ISSN 0002-7863, 03/2015, Volume 137, Issue 9, pp. 3229 - 3232
We have developed a novel antibody–drug conjugate (ADC) that can selectively deliver the Lck inhibitor dasatinib to human T lymphocytes. This ADC is based on a... 
BREAST-CANCER | SRC/ABL KINASE INHIBITOR | IN-VITRO | ACTIVATION | CHEMOKINE RECEPTOR CXCR4 | BMS-354825 | HUMAN T-LYMPHOCYTES | DASATINIB | CELL-RECEPTOR | CHEMISTRY, MULTIDISCIPLINARY | RATIONAL DESIGN | Antibodies - chemistry | Humans | Dasatinib - chemistry | Immunoconjugates - administration & dosage | Immunoconjugates - chemistry | Receptors, CXCR4 - metabolism | Dasatinib - pharmacology | Lymphocyte Specific Protein Tyrosine Kinase p56(lck) - antagonists & inhibitors | Dasatinib - administration & dosage | Receptors, CXCR4 - immunology | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | HEK293 Cells | T-Lymphocytes - immunology | Immunosuppressive Agents - pharmacology | Trastuzumab - immunology | Immunosuppressive Agents - administration & dosage | Immunosuppressive Agents - chemistry | T cells | Research | Antibody-drug conjugates
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Putting CART cells in idle
Science, ISSN 0036-8075, 07/2019, Volume 365, Issue 6448, p. 41
T cells | Dasatinib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia
by Shah, NP
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2019, Volume 17, Issue 5, pp. 611 - 613
The NCCN Guidelines for Chronic Myeloid Leukemia (CML) criteria for discontinuation of tyrosine kinase inhibitor (TKI) therapy have not seen significant... 
ONCOLOGY | IMATINIB | DASATINIB
Journal Article
Details down arrow
9. Full Text SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma
by Schuetze, Scott M and Wathen, J. Kyle and Lucas, David R and Choy, Edwin and Samuels, Brian L and Staddon, Arthur P and Ganjoo, Kristen N and von Mehren, Margaret and Chow, Warren A and Loeb, David M and Tawbi, Hussein A and Rushing, Daniel A and Patel, Shreyaskumar R and Thomas, Dafydd G and Chugh, Rashmi and Reinke, Denise K and Baker, Laurence H
Cancer, ISSN 0008-543X, 03/2016, Volume 122, Issue 6, pp. 868 - 874
BACKGROUND Dasatinib exhibited activity in preclinical models of sarcoma. The Sarcoma Alliance for Research through Collaboration (SARC) conducted a... 
adaptive | dasatinib | phase 2 | sarcoma | Bayesian | Choi | SOFT-TISSUE SARCOMAS | PAZOPANIB | SUBTYPES | CELL LINES | CANCER | CHRONIC MYELOID-LEUKEMIA | IN-VITRO | INHIBITION | ONCOLOGY | CLINICAL-TRIALS | IMATINIB | Osteosarcoma - drug therapy | Humans | Middle Aged | Rhabdomyosarcoma - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Neoplasm Grading | Antineoplastic Agents - adverse effects | Adult | Female | Rhabdomyosarcoma - drug therapy | Drug Administration Schedule | Leiomyosarcoma - pathology | Dasatinib - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Sarcoma - drug therapy | Sarcoma - pathology | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Dasatinib - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Bayes Theorem | Leiomyosarcoma - drug therapy | Aged | Dasatinib - adverse effects | Osteosarcoma - pathology | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034
by Shah, Neil P and Rousselot, Philippe and Schiffer, Charles and Rea, Delphine and Cortes, Jorge E and Milone, Jorge and Mohamed, Hesham and Healey, Diane and Kantarjian, Hagop and Hochhaus, Andreas and Saglio, Giuseppe
American Journal of Hematology, ISSN 0361-8609, 09/2016, Volume 91, Issue 9, pp. 869 - 874
Dasatinib was approved at 100 mg once daily for imatinib‐resistant or ‐intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on... 
RESPONSES | INHIBITION | CML | EUROPEAN LEUKEMIANET | VASCULAR EVENTS | HEMATOLOGY | FAILURE | Pancytopenia - chemically induced | Follow-Up Studies | Pleural Effusion - chemically induced | Humans | Leukemia, Myeloid, Chronic-Phase - drug therapy | Dasatinib - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Drug Resistance, Neoplasm | Treatment Outcome | Antineoplastic Agents - therapeutic use | Leukemia, Myeloid, Chronic-Phase - complications | Imatinib Mesylate | Disease-Free Survival | Dasatinib - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Patient Safety | Dasatinib - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications | Antimitotic agents | Tyrosine | Oncology, Experimental | Clinical trials | Research | Chronic myeloid leukemia | Antineoplastic agents | Pulmonary hypertension | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy
by Sun, Jingjing and Liu, Yanhua and Chen, Yichao and Zhao, Wenchen and Zhai, Qianyu and Rathod, Sanjay and Huang, Yixian and Tang, Suoqin and Kwon, Yong Tae and Fernandez, Christian and Venkataramanan, Raman and Li, Song
Journal of Controlled Release, ISSN 0168-3659, 07/2017, Volume 258, pp. 43 - 55
Two novel prodrug polymers POEG- -PSSDas (redox-sensitive) and POEG- -PCCDas (redox-insensitive), which consist of poly(oligo(ethylene glycol) methacrylate)... 
Prodrug micelles | Dasatinib | Redox responsive | Co-delivery | Doxorubicin | DESIGN | DRUG-DELIVERY | OVARIAN-CANCER | ANTITUMOR-ACTIVITY | CHEMISTRY, MULTIDISCIPLINARY | CHRONIC MYELOID-LEUKEMIA | PACLITAXEL | BREAST-CANCER CELLS | FAMILY KINASE INHIBITOR | IMATINIB | PHARMACOLOGY & PHARMACY | MULTIDRUG-RESISTANCE | Prodrugs - administration & dosage | Doxorubicin - therapeutic use | Humans | Dasatinib - pharmacokinetics | Delayed-Action Preparations - chemistry | Polyethylene Glycols - chemistry | Drug Delivery Systems | Micelles | Female | Antibiotics, Antineoplastic - pharmacokinetics | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | Cell Survival - drug effects | Oxidation-Reduction | Dasatinib - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Animals | Dasatinib - administration & dosage | Antibiotics, Antineoplastic - therapeutic use | Prodrugs - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Mice, Inbred BALB C | Prodrugs - therapeutic use | Neoplasms - pathology | Ethylene glycol | Anthracyclines | Chemotherapy | Polymers | Analysis | Cancer | Tyrosine | Medical colleges | Pharmacogenetics | Pharmacy | Physiological aspects | Drugstores | co-delivery | dasatinib | doxorubicin | prodrug micelles | redox responsive
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
by Ishida, Yoji and Murai, Kazunori and Yamaguchi, Kohei and Miyagishima, Takuto and Shindo, Motohiro and Ogawa, Kazuei and Nagashima, Takahiro and Sato, Shinji and Watanabe, Reiko and Yamamoto, Satoshi and Hirose, Takayuki and Saitou, Souich and Yonezumi, Masakatsu and Kondo, Takeshi and Kato, Yuichi and Mochizuki, Noboru and Ohno, Keiko and Kishino, Satoshi and Kubo, Kohmei and Oyake, Tatsuo and Ito, Shigeki and Inter-Michinoku Dasatinib Study Gr and Inter-Michinoku Dasatinib Study Group (IMIDAS) and the Inter-Michinoku Dasatinib Study Group (IMIDAS)
European Journal of Clinical Pharmacology, ISSN 0031-6970, 2/2016, Volume 72, Issue 2, pp. 185 - 193
Dasatinib is a novel, oral, multi-targeted kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL) and Src family kinases. The study investigated... 
Dasatinib | Pharmacodynamics | Biomedicine | Half maximal inhibitory concentration | Phamacokinetics | Pharmacology/Toxicology | Molecular response | CELLS | SAFETY | TYROSINE KINASE | NILOTINIB | PHILADELPHIA-CHROMOSOME | IMATINIB | DRUGS | BCR-ABL ACTIVITY | PHARMACOLOGY & PHARMACY | INHIBITOR | Leukocytes, Mononuclear - metabolism | Antigens, CD34 - metabolism | Oncogene Protein v-crk - antagonists & inhibitors | Humans | Middle Aged | Oncogene Protein v-crk - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Dasatinib - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Protein Kinase Inhibitors - pharmacokinetics | Leukocytes, Mononuclear - drug effects | Dasatinib - therapeutic use | Treatment Outcome | Dasatinib - pharmacology | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Aged | Dasatinib - adverse effects | Protein Kinase Inhibitors - pharmacology | Phosphotransferases | Analysis | Chronic myeloid leukemia | Pharmacology | Kinetics | Drug therapy | Leukemia | Chronic illnesses
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension
by Guignabert, Christophe and Phan, Carole and Seferian, Andrei and Huertas, Alice and Tu, Ly and Thuillet, Raphaël and Sattler, Caroline and Hiress, Morane Le and Tamura, Yuichi and Jutant, Etienne-Marie and Chaumais, Marie-Camille and Bouchet, Stéphane and Manéglier, Benjamin and Molimard, Mathieu and Rousselot, Philippe and Sitbon, Olivier and Simonneau, Gérald and Montani, David and Humbert, Marc
Journal of Clinical Investigation, ISSN 0021-9738, 09/2016, Volume 126, Issue 9, pp. 3207 - 3218
Pulmonary arterial hypertension (PAH) is a life-threatening disease that can be induced by dasatinib, a dual Src and BCR-ABL tyrosine kinase inhibitor that is... 
MEDICINE, RESEARCH & EXPERIMENTAL | FIBROBLAST GROWTH FACTOR-2 | CELLS | ENDOTHELIAL DYSFUNCTION | THERAPEUTIC STRATEGY | INDUCED APOPTOSIS | TYROSINE KINASE | ARTERIAL-HYPERTENSION | BCR-ABL | ENDOPLASMIC-RETICULUM STRESS | CHRONIC MYELOID-LEUKEMIA | Reactive Oxygen Species - metabolism | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | E-Selectin - blood | Male | Hypertension, Pulmonary - chemically induced | Hypoxia - metabolism | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Adult | Female | Intercellular Adhesion Molecule-1 - blood | Antineoplastic Agents - pharmacology | Genetic Predisposition to Disease | Imatinib Mesylate - pharmacology | Cells, Cultured | Rats | Mitochondria - metabolism | Vascular Cell Adhesion Molecule-1 - blood | Dasatinib - pharmacology | Animals | Lung - drug effects | Dasatinib - adverse effects | Hemodynamics | Lung - blood supply | Apoptosis | Dasatinib | Research | Health aspects | Pulmonary hypertension | Risk factors | Scholarships & fellowships | Toxicity | Mortality | Rodents | Leukemia | Hypoxia | Grants | Laboratory animals | Experiments | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases
by Boddu, Prajwal and Gibbons, Jamie and Burger, Jan and Sivina, Mariela and Thakral, Beenu and Kanagal-Shamanna, Rashmi and Ferrajoli, Alessandra
Leukemia & Lymphoma, ISSN 1042-8194, 05/2019, Volume 60, Issue 6, pp. 1568 - 1571
THERAPY | DASATINIB | ONCOLOGY | HEMATOLOGY | IMATINIB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
by Ravandi, Farhad and O'Brien, Susan M and Cortes, Jorge E and Thomas, Deborah M and Garris, Rebecca and Faderl, Stefan and Burger, Jan A and Rytting, Michael E and Ferrajoli, Alessandra and Wierda, William G and Verstovsek, Srdan and Champlin, Richard and Kebriaei, Partow and McCue, Deborah A and Huang, Xuelin and Jabbour, Elias and Garcia‐Manero, Guillermo and Estrov, Zeev and Kantarjian, Hagop M
Cancer, ISSN 0008-543X, 12/2015, Volume 121, Issue 23, pp. 4158 - 4164
BACKGROUND The long‐term efficacy of a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic... 
dasatinib | acute lymphoblastic leukemia | chemotherapy | combination | Philadelphia chromosome | ADULT PATIENTS | ACUTE LYMPHOCYTIC-LEUKEMIA | REGIMEN | HYPER-CVAD | PONATINIB | THERAPY | ONCOLOGY | IMATINIB | MRD | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Methotrexate - therapeutic use | Cyclophosphamide - therapeutic use | Neoplasm, Residual | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Philadelphia Chromosome | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Dasatinib - therapeutic use | Treatment Outcome | Cytarabine - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Dexamethasone - therapeutic use | Dasatinib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - therapeutic use | Methotrexate - administration & dosage | Aged | Dasatinib | Chemotherapy | Usage | Care and treatment | Lymphocytic leukemia | Stem cells | Dosage and administration | Transplantation | Diagnosis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text How Does One Decide Which Tyrosine Kinase Inhibitor To Use for the Initial Treatment of Chronic-Phase Chronic Myeloid Leukemia? Reply
by Cortes, JE and Hochhaus, A
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 02/2017, Volume 35, Issue 5
ONCOLOGY | IMATINIB | MOLECULAR RESPONSE | DASATINIB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
by Yilmaz, Musa and Lahoti, Amit and O'Brien, Susan and Nogueras‐González, Graciela M and Burger, Jan and Ferrajoli, Alessandra and Borthakur, Gautam and Ravandi, Farhad and Pierce, Sherry and Jabbour, Elias and Kantarjian, Hagop and Cortes, Jorge E
Cancer, ISSN 0008-543X, 11/2015, Volume 121, Issue 21, pp. 3894 - 3904
BACKGROUND Chronic use of tyrosine kinase inhibitors (TKIs) may lead to previously unrecognized adverse events. This study evaluated the incidence of acute... 
dasatinib | nilotinib | imatinib | glomerular filtration rate changes | tyrosine kinase inhibitor | kidney injury | outcome | chronic myeloid leukemia (CML) | CHRONIC MYELOGENOUS LEUKEMIA | RENAL-FAILURE SECONDARY | TUMOR LYSIS SYNDROME | TUBULAR REGENERATION | ONCOLOGY | PDGF | IMATINIB MESYLATE TREATMENT | IN-VIVO | MESANGIAL CELLS | GROWTH-FACTOR | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Protein Kinase Inhibitors - adverse effects | Glomerular Filtration Rate - physiology | Incidence | Dose-Response Relationship, Drug | Renal Insufficiency, Chronic - epidemiology | Young Adult | Creatinine - metabolism | Glomerular Filtration Rate - drug effects | Imatinib Mesylate - therapeutic use | Kidney - metabolism | Imatinib Mesylate - adverse effects | Aged, 80 and over | Adult | Female | Acute Kidney Injury - chemically induced | Retrospective Studies | Kidney - physiopathology | Kidney - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Imatinib Mesylate - pharmacology | Dasatinib - therapeutic use | Treatment Outcome | Pyrimidines - pharmacology | Dasatinib - pharmacology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Pyrimidines - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Aged | Dasatinib - adverse effects | Protein Kinase Inhibitors - pharmacology | Acute Kidney Injury - epidemiology | Renal Insufficiency, Chronic - chemically induced | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Dasatinib | Care and treatment | Myelocytic leukemia | Analysis | Dosage and administration | Nonlymphoid leukemia | Diagnosis | Glomerular filtration rate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights